JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $557.18M
Last updated: Nov 17, 2026 at 11:05 AM ET
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) Financials: Revenue, Profit and Cash Flow
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares reported revenue of $20.69M for the fiscal year ended Sep 30, 2025, down 12.0% from the year before. That year, net income was $1.19M with a net margin of 5.8%, operating cash flow was $2.90M and free cash flow was -$3.73M. The quarter ended Jun 30, 2026 had revenue of $8.92M and net income of -$107.73K.
Revenue and Margins
The operating margin was 2.9% in the fiscal year ended Sep 2025, the lowest of the 8 years shown. Over the 7 years to Sep 2025, revenue fell from $20.91M, a compound annual decline of 0.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $20.69M | -12.0% | 29.2% | 2.9% | 5.8% |
| Sep 2024 | $23.50M | +18.6% | 40.4% | 15.5% | 15.6% |
| Sep 2023 | $19.82M | +3.3% | 34.2% | 14.5% | 14.5% |
| Sep 2022 | $19.19M | -7.6% | 32.3% | 11.1% | 14.1% |
| Sep 2021 | $20.76M | +28.2% | 30.6% | 12.7% | 12.7% |
| Sep 2020 | $16.19M | -20.5% | 34.0% | 14.5% | 13.6% |
| Sep 2019 | $20.37M | -2.6% | 36.9% | 21.6% | 17.9% |
| Sep 2018 | $20.91M | N/A | 36.6% | 20.2% | 17.6% |
Income Statement
In the fiscal year ended Sep 2025, net income fell 67.7% from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.69M | $23.50M | $19.82M | $19.19M | $20.76M | $16.19M | $20.37M | $20.91M |
| Cost of revenue | $14.64M | $14.00M | $13.04M | $12.99M | $14.40M | $10.70M | $12.86M | $13.25M |
| Gross profit | $6.04M | $9.50M | $6.78M | $6.20M | $6.36M | $5.50M | $7.51M | $7.66M |
| Research and development | $1.56M | $1.50M | $1.54M | $1.89M | $1.57M | $1.26M | $1.13M | $1.20M |
| Operating income | $608.18K | $3.64M | $2.87M | $2.13M | $2.63M | $2.35M | $4.40M | $4.23M |
| Net income | $1.19M | $3.68M | $2.88M | $2.71M | $2.63M | $2.21M | $3.65M | $3.68M |
| EBITDA | $958.86K | $3.98M | $3.09M | $3.11M | $3.24M | $2.79M | $4.75M | $4.60M |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.92M | $10.81M | $4.94M | $9.88M | $4.94M | $12.95M | $6.47M | $10.56M | $5.28M | $9.57M | $4.78M | $10.25M |
| Gross profit | $2.40M | $3.64M | $1.27M | $2.53M | $1.27M | $5.81M | $2.91M | $3.80M | $1.90M | $3.25M | $1.67M | $3.63M |
| Operating income | -$644.45K | $1.06M | -$227.11K | -$454.21K | -$227.11K | $2.41M | $1.20M | $1.23M | $614.62K | $1.10M | $547.90K | $1.77M |
| Net income | -$107.73K | $1.28M | -$44.50K | -$89.01K | -$44.50K | $1.88M | $940.92K | $1.79M | $897.05K | $1.11M | $555.94K | $1.77M |
Balance Sheet
As of Sep 2025, short-term debt of $18.91M exceeded cash and equivalents by $11.45M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $53.37M | $45.80M | $32.90M | $20.94M | $21.90M | $20.82M | $20.36M | $18.68M |
| Current assets | $44.14M | $42.82M | $31.12M | $18.90M | $19.42M | $18.16M | $17.70M | $15.61M |
| Cash and equivalents | $7.46M | $8.14M | $6.93M | $4.79M | $3.67M | $1.66M | $1.94M | $853.30K |
| Total liabilities | $23.80M | $17.25M | $8.92M | $5.70M | $7.87M | $10.01M | $9.66M | $9.68M |
| Short-term debt | $18.91M | $11.51M | N/A | N/A | N/A | $2.65M | $2.87M | $712.53K |
| Shareholder equity | $29.64M | $28.82M | $23.98M | $15.24M | $14.03M | $10.80M | $10.71M | $9.00M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $55.84M | $55.84M | $53.37M | $53.37M | $48.52M | $48.52M | $48.52M | $45.80M | $45.80M | $41.16M | $41.16M | $32.90M |
| Total liabilities | $25.69M | $25.69M | $23.80M | $23.80M | $20.77M | $20.77M | $20.77M | $17.25M | $17.25M | $15.01M | $15.01M | $8.92M |
| Cash and equivalents | $9.08M | $9.08M | $7.46M | $7.46M | $11.13M | $11.13M | $11.13M | $8.14M | $8.14M | $8.87M | $8.87M | $6.93M |
| Shareholder equity | $30.32M | $30.32M | $29.64M | $29.64M | $27.91M | $27.91M | $27.91M | $28.82M | $28.82M | $26.24M | $26.24M | $23.98M |
Cash Flow
In the fiscal year ended Sep 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.90M | -$1.21M | $3.11M | $1.58M | $5.84M | $2.50M | -$1.33M | -$2.39M |
| Capital expenditures | $6.63M | $1.12M | $113.94K | $40.17K | $42.88K | $142.32K | $73.33K | $187.68K |
| Free cash flow | -$3.73M | -$2.33M | $2.99M | $1.54M | $5.80M | $2.36M | -$1.40M | -$2.58M |
| Investing cash flow | -$10.79M | -$9.51M | N/A | -$120.90K | -$1.07M | -$1.96M | $126.94K | $1.96M |
| Financing cash flow | $7.35M | $11.65M | $6.91M | $121.86K | -$2.87M | -$343.91K | $2.36M | -$3.19M |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$934.42K | $341.55K | $2.56M | $5.12M | $1.28M | -$1.26M | -$628.65K | $50.00K | $25.00K | $362.91K | $181.46K | $2.74M |
| Capital expenditures | $1.79M | $4.58M | $1.03M | $2.05M | $1.03M | $61.27K | $30.64K | $83.68K | $41.84K | $102.92K | $51.46K | $11.01K |
| Free cash flow | -$2.72M | -$4.24M | $1.54M | $3.07M | $255.45K | -$1.32M | -$659.29K | -$33.68K | -$16.84K | $259.99K | $129.99K | $2.73M |
Frequently Asked Questions About ZJYL
What is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares' annual revenue?
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares reported revenue of $20.69M for the fiscal year ended Sep 30, 2025.
How fast is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares' revenue growing?
Revenue was down 12.0% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.5%.
Is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares profitable?
Yes. JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares reported net income of $1.19M for the fiscal year ended Sep 30, 2025, with a net margin of 5.8%.
How much free cash flow does ZJYL generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of $2.90M minus capital expenditures of $6.63M produced free cash flow of -$3.73M.
How much debt does JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares have?
The balance sheet dated Sep 30, 2025 reported short-term debt of $18.91M and cash and equivalents of $7.46M.
ZJYL pages: Overview, Financials